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Summary 
Atrial fibrillation is a common condition and 
carries the risk of cerebral thromboembolism. The 
CHAdS2 score is often used to stratify this risk. 
Anticoagulant therapy with warfarin significantly 
reduces this risk, but there are limitations to its 
use. This has prompted the use of antiplatelet 
drugs. Patients with mitral valve disease should 
always be considered for anticoagulant therapy. 
However for other patients with atrial fibrillation, 
the decision about which drug to use is based 
on the patient's risk of thromboembolism. in 
addition to stroke prevention, management is 
directed towards restoring and maintaining sinus 
rhythm or controlling the ventricular rate in those 
for whom permanent atrial fibrillation is accepted. 
For some patients percutaneous (catheter-
directed) creation of lesions within the left atrium 
may be effective in maintaining sinus rhythm.
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introduction
Atrial fibrillation is the most common sustained cardiac 
arrhythmia, occurring in 1–2% of the population of the 
developed world.1 Its prevalence increases with age so 
that around 8% of people over 80 years of age have atrial 
fibrillation.2 It may occur in isolation or secondary to structural 
heart disease, hypertension, myocardial ischaemia and 
infarction, hyperthyroidism, obesity and sleep apnoea. It can 
also develop following cardiac surgery or excess consumption 
of alcohol.3-5 Symptoms include palpitations, dizziness, 
dyspnoea, angina and worsening heart failure.1,3,5 
Atrial fibrillation may be categorised according to its 
presentation (initial, paroxysmal or recurrent, persistent) and 
duration.1 Its management depends on the assessment of 
thromboembolic risk and control of symptoms. In general, 
a decision is made to pursue either a rhythm or rate control 
strategy.1,2,6-8 With rhythm control the aim is to maintain 
the patient in sinus rhythm, while with rate control the aim 
is to control the ventricular rate with medication and accept 
permanent atrial fibrillation.
Assessing stroke risk
Atrial fibrillation carries the risk of cerebral thromboembolism2 
and may be responsible for one in five of all strokes.1 Systemic 
thromboembolism, leading to stroke, transient ischaemic 
attacks or embolisation to other sites, is the most dreaded 
complication of atrial fibrillation. Anticoagulant therapy reduces 
this risk. The decision to use anticoagulant or antiplatelet 
therapy is dictated by the patient's risk of these events. 
Those with mitral valve disease should always be considered 
for anticoagulant therapy.1,2 The CHADS2 score has been 
commonly used to stratify risk (see Box 1).1-3 A score of 2 or 
more is generally taken to indicate a risk of thromboembolism 
which may warrant warfarin therapy, depending on the 
patient's haemorrhagic risk, although even those with only 
one risk factor (CHADS2 score of 1) may benefit from oral 
anticoagulants (Fig. 1).1 
The CHA2DS2-VASc score, introduced by the European Society 
of Cardiology, provides a more comprehensive stroke risk 
assessment. It extends the CHADS2 score with points also 
being allotted for female sex, vascular disease and age 65–74 
years.1 The European guidelines also introduced the concept 
of assessing the bleeding risk (see Box 2). Any patient with a 
bleeding score of 3 or above is at high risk and regular review 
during antithrombotic therapy is recommended. 
Box 1
CHAdS2 score: stratifying risk of stroke in patients with 
atrial fibrillation
Congestive heart failure 1 point
Hypertension 1 point
Age ≥ 75 years 1 point
diabetes 1 point
Systemic embolism, including Stroke 2 points 
(previous episode)
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Alternative oral anticoagulants 
Several effective substitutes for warfarin are used for stroke 
prevention in North America and Europe. These include the 
direct thrombin antagonist dabigatran and factor Xa inhibitors 
such as rivaroxaban, apixaban, betrixaban and edoxaban.14 
Dabigatran is the first drug to show non-inferiority to warfarin 
for stroke prevention in atrial fibrillation.4,14-16 The 150 mg 
twice-daily dose was superior to warfarin in efficacy with a 
similar risk of major bleeding whereas 110 mg twice daily was 
non-inferior for efficacy with a reduced risk of major bleeding. 
The risk of intracranial haemorrhage was less with both doses 
of dabigatran than with warfarin.15-18 Rivaroxaban is also an 
effective anticoagulant.19,20 The main advantage of rivaroxaban 
and dabigatran over warfarin is they have more predictable 
pharmacokinetics, and routine anticoagulation monitoring is 
not needed. No interaction between cytochrome P450 enzymes 
and dabigatran has been observed, although P-glycoprotein 
inhibitors such as amiodarone and verapamil may increase 
plasma concentrations of dabigatran and lead to an increased 
bleeding risk. There is also a risk of dabigatran accumulation in 
renal impairment.14 There is no antidote if bleeding occurs with 
dabigatran and rivaroxaban.
These drugs may replace warfarin for thromboembolic 
prophylaxis in atrial fibrillation if their cost-effectiveness can 
Box 2
HASBLed score
Hypertension 1 point
Abnormal liver or kidney function  1 point each
Stroke 1 point
Bleeding 1 point
Labile INRs 1 point
elderly (e.g. >65 years) 1 point
drugs or alcohol 1 point each
Hypertension = systolic blood pressure >160 mmHg
Abnormal renal function = dialysis/renal transplantation/
serum creatinine ≥200 mmol/L
Abnormal liver function = chronic hepatic dysfunction  
(e.g. cirrhosis) or biochemical evidence of significant hepatic 
derangement (e.g. bilirubin 2 x upper limit of normal 
in association with aspartate aminotransferase/alanine 
aminotransferase/alkaline phosphatase 3 x upper limit  
normal etc.)
Bleeding = history of bleeding or a bleeding diathesis
Drugs = concomitant use of antiplatelet or non-steroidal  
anti-inflammatory drugs
Fig. 1
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There are other models for assessing stroke risk. These 
incorporate echocardiographic findings such as left atrial size, 
left ventricular systolic dysfunction and spontaneous echo 
contrast or thrombus in the left atrium.
drug therapies for preventing stroke
For low-risk patients with atrial fibrillation, aspirin, or no 
treatment, may be sufficient. For higher-risk patients, treatment 
options include warfarin, aspirin and clopidogrel. Several 
studies have compared the efficacy of antiplatelet regimens 
to warfarin.9-11 The Birmingham Atrial Fibrillation Treatment 
of the Aged (BAFTA) study showed that warfarin (target INR 
2–3) was superior to aspirin 75 mg daily.10 The ACTIVE-W trial 
showed that clopidogrel plus aspirin was associated with a 
45% increase in the risk of stroke, non-central nervous system 
embolism, myocardial infarction or vascular death compared 
to oral anticoagulation (annual rates for events 5.60% vs 3.93% 
respectively, p=0.0002). However, the cumulative risk of major 
bleeding complications was nearly identical (2.4% vs 2.2% 
per year, p=0.67).11 In summary, warfarin is more effective 
in preventing cerebrovascular events than dual antiplatelet 
therapy, although the danger of major bleeding is similar.11 
The INR is usually maintained between 2 and 3,12 but a higher 
range may be appropriate in patients with prosthetic heart 
valves or rheumatic mitral valve disease. In patients unable to 
take warfarin, adding clopidogrel to aspirin reduces the risk of 
major vascular events by 11%, particularly stroke, but increases 
the risk of major haemorrhage by 57%.13 
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be shown.21 However, for a condition that requires long-term 
prophylaxis there are no long-term data to suggest that they will 
be safe and effective alternatives.
device-based strategies for preventing stroke 
Medical prophylaxis of stroke in patients with atrial fibrillation 
has been plagued by a high risk of bleeding complications, 
frequent drug interactions and a narrow therapeutic range of 
the drugs and hence poor compliance. Alternative approaches 
have been sought and a number of device-based treatments are 
becoming available or being evaluated.
Thrombi have been demonstrated in the left atrial appendage in 
up to 90% of patients with non-valvular atrial fibrillation.22 For 
many years surgeons have combined mitral valve surgery with 
ligation of the left atrial appendage to try and reduce the risk of 
subsequent embolism. 
The Watchman device is delivered by catheter to the left atrial 
appendage. It has been shown to be non-inferior to chronic 
warfarin therapy in patients with a CHADS2 score of more than 1. 
This was despite a peri-procedural complication rate of 10.6% 
which included major bleeding, stroke and sequelae such as 
device or air embolism and pericardial effusion that may have 
Fig. 2
Proposed management of non-valvular atrial fibrillation
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reflected operator inexperience. Most ischaemic strokes occurred 
at the time of the procedure – their subsequent incidence was 
less than in control patients treated with warfarin. These results 
support the hypothesis that thrombus in the left atrial appendage 
is the likely source of embolic stroke in patients with non-
valvular atrial fibrillation, and appear to endorse a role for left 
atrial appendage closure.22,23 Longer-term follow-up is necessary 
before the use of these devices can be generally recommended.
rate control
Most patients with atrial fibrillation are managed by controlling 
the ventricular rate. In patients with minimal symptoms, 
aggressive attempts to maintain sinus rhythm have not 
been shown to reduce mortality, improve quality of life, or 
prevent heart failure or thromboembolic complications.6-8 
The ventricular rate may be controlled using beta blockers, 
non-dihydropyridine calcium channel blockers (for example 
verapamil) or digoxin.1,3,5 However, beta blockers should be 
avoided in patients with asthma, and digoxin and calcium 
channel blockers should be avoided in those with pre-excitation. 
Lenient control (resting heart rate less than 110 beats/minute) 
is as effective as strict rate control and is easier to achieve.6 
Anticoagulation should be continued in these patients (Fig. 2).
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antithrombotic regimens offer an alternative to warfarin as do 
techniques for left atrial appendage occlusion.
If the management of atrial fibrillation is directed towards 
restoring and maintaining sinus rhythm, percutaneous (catheter-
directed) creation of lesions within the left atrium may be 
warranted, but for most patients with permanent atrial fibrillation 
controlling the ventricular rate is the most practical strategy.
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rhythm control
The severity of symptoms usually drives the decision to pursue 
a rhythm control strategy. In symptomatic patients it may 
be reasonable to attempt to restore sinus rhythm. For those 
without structural heart disease who present within 48 hours of 
the onset of atrial fibrillation, immediate cardioversion (electrical 
or drug) may be attempted under cover of unfractionated 
or low molecular weight heparin.1 Those who present later 
should be presumed to have left atrial thrombus (unless this 
has been excluded with a trans-oesophageal echocardiogram) 
and cardioversion should be deferred until they have been 
effectively anticoagulated for at least three weeks.1,3,5 
Anticoagulants should be continued for at least four weeks after 
successful cardioversion even if transoesophageal echo has 
excluded left atrial thrombus.2,3
Although amiodarone is the most effective antiarrhythmic drug 
for maintenance of sinus rhythm its long-term value is limited 
by adverse effects.2,3 Sotalol combines beta blocking and 
antiarrhythmic properties but prolongs the QT interval and may 
provoke torsades de pointes and cardiac arrest,3,5 particularly 
in patients with renal dysfunction and impaired drug clearance 
or hypokalaemia, which may occur with concomitant diuretic 
therapy.23 Intravenous or oral flecainide ('pill in pocket')1,3,5 may 
be effective but should be avoided in those with left ventricular 
dysfunction or ischaemia.24
Dronedarone cannot be recommended as a first-line drug.25 
Although it may not have the pulmonary and thyroid toxicity 
of amiodarone25-27 and is more effective than placebo in 
maintaining sinus rhythm and reducing the ventricular 
rate during recurrent atrial fibrillation,26,28 its use has been 
associated with worsening heart failure and increased mortality 
in patients with severe left ventricular systolic dysfunction.29
Catheter-directed creation of lesions within the left atrium has 
become an acceptable treatment for selected patients who 
have not responded to at least one antiarrhythmic drug. Most 
strategies depend on electrical isolation of the pulmonary veins, 
with successful maintenance of sinus rhythm for 12 months 
in excess of 80% for paroxysmal atrial fibrillation and 70% 
for persistent atrial fibrillation.28,30 However, atrial fibrillation 
may recur and patients may need to remain on medications, 
including anticoagulants. In recent surveys the complication 
rate was 5.9% and included cardiac tamponade, pulmonary vein 
stenosis, stroke, phrenic nerve palsy, atrio-oesophageal fistula 
and death.31,32 For those who are highly symptomatic with 
uncontrolled ventricular rates despite optimal medical therapy, 
atrio-ventricular node ablation and insertion of a permanent 
pacemaker may improve quality of life.
Conclusion
The burden of atrial fibrillation will grow further as populations 
age. The major adverse outcome is embolic stroke. Newer 
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Self-test questions
The following statements are either true or false  
(answers on page 123)
3. A 76-year-old woman with atrial fibrillation, type 2  
diabetes and hypertension should be considered for 
anticoagulation therapy.
4. Dual antiplatelet therapy is more effective than 
warfarin for stroke prevention.
The August issue of NPS RADAR reviews the evidence and place in therapy for:
■■ dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
■■ sitagliptin, vildagliptin and saxagliptin – dipeptidyl peptidase-4 inhibitors ('gliptins') 
for type 2 diabetes mellitus (updated review available online)
Read the full reviews at www.nps.org.au/radar
